RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer

Clinical trial NCT05578287 · UNKNOWN

Trial details

NCT number: NCT05578287
Sponsor: Sun Yat-sen University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Cancer

Start date: 2023-07-18
Primary completion: 2024-12-15
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.